Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (AKs)

PHASE3CompletedINTERVENTIONAL
Enrollment

490

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
Actinic Keratosis
Interventions
DRUG

Imiquimod cream

250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.

DRUG

Placebo cream

250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.

DRUG

Imiquimod cream

250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.

Trial Locations (26)

19034

Philadelphia

22191

Woodbridge

23507

Norfolk

33134

Coral Gables

33401

West Palm Beach

35205

Birmingham

37203

Nashville

40202

Louisville

46032

Carmel

46617

South Bend

47713

Evansville

60005

Arlington Heights

61820

Champaign

68144

Omaha

72205

Little Rock

75246

Dallas

77030

Houston

77058

Houston

78229

San Antonio

87106

Albuquerque

89509

Reno

91436

Encino

92083

Vista

97223

Portland

06052

New Britain

06511

New Haven

Sponsors
All Listed Sponsors
lead

Graceway Pharmaceuticals, LLC

INDUSTRY